- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pharma Expects Push-Back on Cancer Drug Costs
After Steven Miller, CMO at Express Scripts, announced last week that his company would like to influence the oncology market, Pharma seems to have paid heed.
Payers are likely to put pressure on drugmakers to lower the cost of cancer medicines, particularly when alternative treatments are available, the head of Novartis' pharma division said on Tuesday.
"I think there will be increased pressure on oncology prices," David Epstein, head of Novartis' pharmaceutical division told an analyst call after the company reported fourth-quarter results.
The high price of new immuno-oncology drugs which are expected to be used in combination with other medicines would make it necessary to impose a limit on costs, he said.
"I fully expect whenever a payer has good therapeutic equivalents to be able to put pressure on," he said.
Link to the report on Reuters:
Also read:
After Hep C, Express Scripts Aims to Influence Oncology Drug Costs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
